Evidence map›Paper›PMID 40751436›Full record

ArticleThe Journal of infectious diseases2025

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.

Taraz Samandari, Millicent Achola, Jack N Hutter, Grace Mboya, Walter Otieno, Jia Jin Kee, Yunda Huang, John J Aponte, Christian F Ockenhouse, Cynthia K Lee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Taraz SamandariCOVID-19 Prevention Network, Seattle, Washington, USA.ORCID 0000-0003-4830-6108
Millicent AcholaU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Jack N HutterU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Grace MboyaKenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya.
Walter OtienoU.S. Army Medical Research Directorate-Africa, Kisumu, Kenya.
Jia Jin KeeVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Yunda HuangVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
John J ApontePATH Center for Vaccine Innovation and Access, Geneva, Switzerland.ORCID 0000-0002-3014-3673
Christian F OckenhousePATH Center for Vaccine Innovation and Access, Washington, District of Columbia, USA.ORCID 0009-0006-9715-7064
Cynthia K LeePATH Center for Vaccine Innovation and Access, Washington, District of Columbia, USA.
Laura PolakowskiNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.ORCID 0000-0002-5476-7632
Margaret YacovoneNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA.ORCID 0000-0002-6983-8560
Asa TapleyVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-3206-1708
Sufia DadabhaiJohns Hopkins Bloomberg School of Public Health, Blantyre, Malawi.
Nonhlanhla N MkhizeNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Haajira KaldineNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Sinethemba BhebheNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
Penny L MooreNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
John HuralVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Nigel GarrettDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-4530-234X
James G KublinVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
Leadership Group for a Global HIV Vaccine Clinical Trials NetworkU01AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI COREY, LAWRENCE · 2006 to 2010
$181.5M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials NetworkU01AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SELF, STEVEN G. · 2006 to 2010
$53.8M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASEST32AI007044 · NIAID · UNIVERSITY OF WASHINGTON · PI DAVID Neal FREDRICKS · 1985 to 2026
$14.6M
Bill & Melinda Gates Foundation INV-007217Gates Foundation INV007217National Institute of Allergy and Infectious DiseasesNIAID NIH HHS T32 AI007044NIAID NIH HHS U01 AI068614NIAID NIH HHS U01 AI068635NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069518NIH HHS 3UM1AI068618-15S1NIH HHS T32AI007044-45NIH HHS UM1 AI068614-14NIH HHS UM1 AI068635
6 · The paper itself

Abstract

mRNA vaccines have emerged as powerful tools for the prevention of infectious diseases, but subclinical malaria may reduce vaccine immunogenicity. We evaluated neutralizing antibody responses in asymptomatic HIV-infected adults with and without polymerase chain reaction-confirmed Plasmodium falciparum who received either monovalent mRNA-1273 or bivalent mRNA-1273.222 (WA-1 and BA.4/5) booster vaccines. In previous studies, a 50% pseudovirus inhibitory dose neutralizing antibody (ID50) titer of 1000 correlated with 96% efficacy in preventing COVID-19. We observed ID50 geometric mean titers >22 000 in both parasitemic and nonparasitemic participants 1 month after boosting. We conclude that COVID-19 mRNA vaccine antibody responses are unimpaired by concurrent asymptomatic parasitemia.

Indexed as

Antibodies, NeutralizingCOVID-19COVID-19 VaccinesHIV InfectionsMalaria, FalciparumParasitemia2019-nCoV Vaccine mRNA-1273AdultAntibodies, ViralFemaleHumansImmunization, SecondaryMaleMiddle AgedPlasmodium falciparumSARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHIVimmunogenicitymalariamRNA vaccineSARS-CoV-2

Identifiers

PMID40751436
PMCPMC12476267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.